SLFN11 and neoplasm: Future investigation will involve prospective clinical trials in multiple cancer subtypes to determine whether SLFN11 expression predicts tumor response, recurrence, progression, and survival in patients treated with topoisomerase inhibitors, alkylating agents, anti-metabolites, or anti-tumor antibiotics.